Wall Street analysts expect that Viking Therapeutics Inc (NASDAQ:VKTX) will post earnings per share of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings of ($0.14) per share in the same quarter last year, which suggests a positive year over year growth rate of 21.4%. The company is scheduled to issue its next earnings report on Wednesday, March 6th.
According to Zacks, analysts expect that Viking Therapeutics will report full year earnings of ($0.44) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.41). For the next financial year, analysts anticipate that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.55) to ($0.39). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01.
VKTX stock opened at $12.33 on Wednesday. The company has a market cap of $833.44 million, a price-to-earnings ratio of -15.61 and a beta of 2.92. Viking Therapeutics has a one year low of $2.24 and a one year high of $24.00.
In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of Viking Therapeutics stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 3.90% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in VKTX. Janney Montgomery Scott LLC bought a new stake in Viking Therapeutics in the second quarter valued at $114,000. Strs Ohio bought a new stake in Viking Therapeutics in the second quarter valued at $120,000. Cubist Systematic Strategies LLC bought a new stake in Viking Therapeutics in the second quarter valued at $129,000. First Mercantile Trust Co. bought a new stake in Viking Therapeutics in the third quarter valued at $131,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Viking Therapeutics in the second quarter valued at $144,000. Institutional investors and hedge funds own 53.56% of the company’s stock.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
Recommended Story: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.